Biopharma · FDA Approvals · Stock
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial po…
Dated catalysts for PTN, including recently decided ones.
Every first-hand event for PTN, newest first.
Palatin Advances PL2000 MC4R Agonist to Phase 1 in H1 2027
Palatin is advancing its lead lipidated PL2000 MC4R-selective peptide through ongoing IND-enabling studies and CMC activities. The company targets initiation of a Phase 1 SAD/MAD study in the first half of calendar 2027, with initial data expected in the second half of 2027. Preclinical data support once-weekly dosing and minimal MC1R activity to reduce hyperpigmentation risk.
Palatin Presents Preclinical Data on MC4R Agonist PL2001 at ObesityWeek 2026
Palatin presented new preclinical data at ObesityWeek 2026 showing its novel MC4R-selective peptide agonists (including lead PL2001) have potent MC4R activity with >100-fold selectivity over MC1R, significant body weight and food intake reductions in DIO mice, extended half-life supporting once-weekly dosing via lipidation, and no cardiovascular effects at efficacious doses. PL2001 was selected as development candidate with first-in-human studies targeted for H1 2027.
Companies in the same sector closest to PTN in market value.